2023 World Conference on Lung Cancer (Posters)-P2.09. FURVENT, Phase 3 Trial Testing Furmonertinib vs Chemotherapy as First-Line Treatment for Advanced NSCLC with EGFR exon 20 Insertions

P2.09. FURVENT, Phase 3 Trial Testing Furmonertinib vs Chemotherapy as First-Line Treatment for Advanced NSCLC with EGFR exon 20 Insertions - PDF(Abstract)

Back to course

Pdf Summary

The FURVENT phase 3 trial is investigating the efficacy of furmonertinib compared to chemotherapy as a first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertions. These mutations occur in approximately 2% of NSCLC cases and 9% of all EGFR mutations in NSCLC. Currently, platinum-based chemotherapy is the standard treatment for these patients. Furmonertinib is an oral EGFR inhibitor that specifically targets EGFR exon 20 insertions and other mutations.<br /><br />Preliminary data from a study testing furmonertinib as a first-line treatment showed a promising overall response rate of 70% with acceptable safety at a daily dose of 240 mg. The FURVENT study is a global, randomized, multicenter, phase 3 trial that aims to enroll approximately 375 treatment-naïve NSCLC patients with EGFR exon 20 insertions. Patients will be randomized 1:1:1 to receive either furmonertinib at a dose of 160 mg or 240 mg daily, or platinum-based chemotherapy followed by maintenance therapy. Stratification factors include the presence or history of central nervous system metastases, geographic region, and sex at birth.<br /><br />The primary endpoint of the study is progression-free survival, comparing the treatment arms based on blinded independent central review assessment. The key secondary endpoint is overall survival. Patients who experience disease progression after chemotherapy in the chemotherapy arm will be eligible to participate in the crossover phase of the trial and receive furmonertinib therapy.<br /><br />Currently, the study is still ongoing, and the clinical trial information can be found using the identifier NCT05607550. This research is part of Track 12, which focuses on targeted therapy for metastatic non-small cell lung cancer. The results of this phase 3 trial will provide valuable insights into the effectiveness of furmonertinib compared to chemotherapy as a first-line treatment for advanced NSCLC patients with EGFR exon 20 insertions.

Asset Subtitle

Alexander Spira

Meta Tag

Speaker Alexander Spira

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

FURVENT phase 3 trial

furmonertinib

chemotherapy

first-line treatment

advanced non-small cell lung cancer

NSCLC

EGFR exon 20 insertions

platinum-based chemotherapy

oral EGFR inhibitor

progression-free survival